|  |
| --- |
| Supplementary table 2 Univariate analysis of factors affecting PFS and OS. |
| Variables | PFS |  | OS |
| Median PFS (95%CI) in months | P value |  | Median OS (95%CI) in months | P value |
| Age (years)≤80>80 |  |  | 0.992 |  |  |  | 0.414 |
| 26 (0.00-82.34) |  |  | 70 (31.40-108.60) |  |
| 31 (8.83-53.18) |  |  | 32 (8.44-55.56) |  |
| Gender | 0.801 |  |  |  | 0.793 |
| Female | 10 (-) |  |  | 12 (-) |  |
| Male | 31 (20.03-41.97) |  |  | 69 (34.47-103.53) |  |
| BMI (kg/m2) |  |  | 0.002 |  |  |  | 0.013 |
| ≤22.77 | 69 (17.37-120.63) |  |  | 79 (54.44-103.56) |  |
| >22.77 | 10 (8.01-11.99) |  |  | 45 (19.31-70.69) |  |
| Smoking index |  |  | 0.120 |  |  |  | 0.027 |
| ≤1100 | 32 (0.00-69.15) |  |  | 77 (27.43-126.57) |  |
| >1100 | 25 (4.55-45.45) |  |  | 36 (25.77-46.23) |  |
| Performance status |  |  | 0.078 |  |  |  | 0.029 |
| 0/1 | 32 (0.00-78.66) |  |  | 77 (41.17-112.83) |  |
| 2 | 18 (3.54-32.46) |  |  | 36 (15.75-56.25) |  |
| aCCI |  |  | 0.919 |  |  |  | 0.797 |
| ≤5 | 26 (0.00-54.44) |  |  | 77 (28.94-125.06) |  |
| >5 | 31 (0.00-69.41) |  |  | 48 (8.39-87.61) |  |
| Comorbidity |  |  | 0.473 |  |  |  | 0.206 |
| No | 32 (0.00-103.34) |  |  | 87 (59.18-114.82) |  |
| Yes | 23 (6.08-39.92) |  |  | 45 (28.80-61.20) |  |
| Tumor location |  |  | 0.143 |  |  | 0.122 |
| Left lung | 70 (0.00-180.51) |  |  | 70 (7.28-132.72) |  |
| Right lung | 31 (17.51-44.50) |  |  | 50 (14.39-85.61) |  |
| T-stage |  |  | 0.379 |  |  |  | 0.212 |
| T1 | 13 (7.95-18.05) |  |  | 48 (1.34-94.66) |  |
| T2 | 32 (0.00-81.37) |  |  | 77 (25.89-128.11) |  |
| T3 | 31 (0.00-66.15) |  |  | 46 (0.00-102.74) |  |
| N-stage |  |  | 0.159 |  |  |  | 0.156 |
| N0 | 31 (19.91-42.09) |  |  | 50 (21.80-78.21) |  |
| N1 | 135 (-) |  |  | 135 (-) |  |
| TNM-stage |  |  | 0.555 |  |  |  | 0.746 |
| I | 16 (9.15-22.85) |  |  | 48 (0.16-95.84) |  |
| IIA | 50 (0.00-115.08) |  |  | 50 (0.00-115.08) |  |
| IIB | 31(0.00-101.56) |  |  | 69 (3.43-134.57) |  |
| SIRI |  |  | 0.088 |  |  |  | 0.207 |
| ≤0.79 | 11 (8.43-13.57) |  |  | 37 (16.49-57.51) |  |
| >0.79 | 32 (0.00-92.61) |  |  | 70 (30.09-109.91) |  |
| NLR |  |  | 0.115 |  |  |  | 0.021 |
| ≤2.63 | 68 (0.00-155.18) |  |  | 101 (44.52-157.48) |  |
| >2.63 | 26 (11.09-40.91) |  |  | 37 (19.97-54.03) |  |
| PLR |  |  | 0.018 |  |  |  | 0.006 |
| ≤150.36 | 68 (10.88-125.12) |  |  | 101 (45.42-156.58) |  |
| >150.36 | 16 (3.27-28.73) |  |  | 31 (16.82-45.18) |  |
| PNI |  |  | 0.304 |  |  |  | 0.104 |
| ≤41.1 | 23 (0.00-99.23) |  |  | 37 (0.00-99.37) |  |
| >41.1 | 31 (14.85-47.15) |  |  | 50 (11.23-88.77) |  |
| CAR |  |  | 0.071 |  |  |  | 0.026 |
| ≤0.91 | 32 (0.00-80.74) |  |  | 70 (32.53-107.47) |  |
| >0.91 | 10 (0.00-25.10) |  |  | 12 (0.00-44.41) |  |
| LCR |  |  | 0.337 |  |  |  | 0.222 |
| ≤0.03 | 23 (0.00-56.36) |  |  | 37 (0.00-101.16) |  |
| >0.03 | 32 (0.00-67.46) |  |  | 70 (38.08-101.92) |  |
| RBC (10^12/L) |  |  | 0.156 |  |  |  | 0.316 |
| ≤4.09 | 68 (0.10-135.91) |  |  | 70 (27.93-112.07) |  |
| >4.09 | 16 (7.80-24.20) |  |  | 48 (27.19-68.81) |  |
| Hb (g/L) |  |  | 0.116 |  |  |  | 0.137 |
| ≤130 | 32 (0.00-85.58) |  |  | 70 (19.50-120.50) |  |
| >130 | 18 (0.48-35.53) |  |  | 36 (28.05-43.95) |  |
| Time from diagnosis to SBRT (days) |  | 0.421 |  |  | 0.174 |
| ≤232 | 31 (19.00-43.00) |  |  | 70 (36.96-103.04) |  |
| >232 | 32 (0.00-85.68) |  |  | 32 (0.00-85.68) |  |
| Size (cm) |  |  | 0.275 |  |  |  | 0.197 |
| ≤6.4 | 25 (11.19-38.81) |  |  | 37 (18.23-55.77) |  |
| >6.4 | 70 (13.77-126.23) |  |  | 101 (56.49-145.51) |  |
| PTV (cm3) |  |  | 0.153 |  |  |  | 0.032 |
| ≤57.9 | 68 (0.00-145.88) |  |  | 87 (58.71-115.29) |  |
| >57.9 | 25 (11.43-38.57) |  |  | 37 (20.80-53.20) |  |
| BED (Gy) |  | 0.951 |  |  | 0.934 |
| ≤100 | 26 (0.00-72.41) |  |  | 69 (37.03-100.93) |  |
| >100 | 31 (14.28-47.72) |  |  | 48 (0.00-106.15) |  |
| Systemic therapy |  |  | 0.951 |  |  |  | 0.732 |
| Yes | 10.0 (0.00-39.33) |  |  | 45.0 (0.00-107.34) |  |
| No | 31.0 (20.46-41.54) |  |  | 50.0 (22.64-77.36) |  |
| PFS: progression-free survival; OS: overall survival; BMI: body mass index; aCCI: Age-adjusted Charlson Comorbidity Index; SIRI: systemic inflammation response index; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; CAR: C-reactive protein to albumin ratio; LCR: lymphocyte to C-reactive protein ratio; RBC: red blood cell count; Hb: hemoglobin; PTV: planning tumor volume; BED: biological effective dose |